All In Biotech

Drugs by condition

Drugs approved for atrial fibrillation

Brand-name prescription drugs and biologics whose FDA label lists atrial fibrillation as an approved use. Matched on the label phrases: "atrial fibrillation".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

26

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

10

New molecular entities and new biologics

In development

9

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for atrial fibrillation.

All approved drugs for atrial fibrillation, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 136 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Factor Xa Inhibitor (3)

  • Eliquis Apixaban · Bristol Myers Squibb · 2012
  • Xarelto Rivaroxaban · Janssen Pharms · 2011
  • Eliquis Apixaban · Bristol · 2025

Antiarrhythmic (2)

  • Multaq Dronedarone Hydrochloride · Sanofi Aventis US · 2009
  • Tikosyn Dofetilide · Pfizer · 1999

Cardiac Glycoside (2)

  • Digoxin Digoxin · Hikma · 2004
  • Lanoxin Digoxin · Advanz Pharma · 1997

Class not listed in FDA's data (19)

Drugs in development for atrial fibrillation

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • REGN7508CenvacibartPhase 312 trials

    Regeneron · Atrial Fibrillation (AF), Venous Thromboembolism (VTE), Venous Thromboembolism

  • REGN9933amrecibartPhase 35 trials

    Regeneron · Atrial Fibrillation (AF), Peripheral Artery Disease (PAD), Venous Thromboembolism (VTE)

  • AbelacimabMAA868Phase 33 trials

    Anthos Therapeutics, Inc. · Atrial Fibrillation (AF), Stroke

  • MilvexianJNJ-70033093, BMS-986177Phase 33 trials

    Johnson & Johnson (Janssen) · Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation, Acute Coronary Syndrome

  • VortosiranPhase 22 trials

    Ribocure Pharmaceuticals AB · Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)

  • AP31969Phase 21 trial

    Acesion Pharma · Atrial Fibrillation (AF)

  • BAY 3670549Phase 21 trial

    Bayer · Atrial Fibrillation

  • HBI-3000sulcardine sulfatePhase 21 trial

    HUYABIO International, LLC. · Atrial Fibrillation

  • PKN605Phase 21 trial

    Novartis · Atrial Fibrillation

2 discontinued brand-name drugs whose label still names it

More on atrial fibrillation: recruiting trials · published research

Related in cardiovascular and metabolic: Type 2 diabetes · Type 1 diabetes · Obesity and weight management · High blood pressure (hypertension) · Heart failure · High cholesterol · High triglycerides · Blood clots (DVT and pulmonary embolism) · Stroke prevention · Coronary artery disease and heart attack

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.